Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

engineered interferon ORB-011

An attenuated, cis-targeted interferon (IFN), with potential immunostimulating and antineoplastic activities. Upon administration, engineered IFN ORB-011 specifically targets, binds to and activates type 1 conventional dendritic cell (cDC1). As these are specific immune cells that specialize in presenting tumor antigens to, and activating, tumor cytotoxic CD8 T cells, ORB-011 may be able to stimulate a specific cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response. ORB-011 is engineered in such a way as to minimize off-target IFN-based binding and thereby avoiding systemic toxicity.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:cis-targeted interferon ORB-011
engineered cytokine ORB-011
engineered IFN ORB-011
Code name:ORB 011
ORB-011
ORB011
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search